Compare ESQ & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | EVO |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 934.1M |
| IPO Year | 2017 | N/A |
| Metric | ESQ | EVO |
|---|---|---|
| Price | $111.95 | $2.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $120.33 | $7.00 |
| AVG Volume (30 Days) | 81.3K | ★ 86.6K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.15 | $1.37 |
| Revenue Next Year | $39.09 | $10.05 |
| P/E Ratio | $80.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.54 | $2.31 |
| 52 Week High | $119.86 | $4.80 |
| Indicator | ESQ | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 58.25 | 47.70 |
| Support Level | $104.58 | $2.63 |
| Resistance Level | $115.69 | $3.78 |
| Average True Range (ATR) | 2.35 | 0.09 |
| MACD | 0.68 | -0.03 |
| Stochastic Oscillator | 87.64 | 37.13 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.